Prospective analysis of liquid biopsies of advanced non-small cell lung cancer patients after progression to targeted therapies using GeneReader NGS platform.

Background: In a significant percentage of advanced non-small cell lung cancer (NSCLC) patients, tumor tissue is unavailable or insufficient for genetic analyses at time to progression. We prospectively analyzed the appearance of genetic alterations associated with resistance in liquid biopsies of advanced NSCLC patients progressing to targeted therapies using the NGS platform.

Methods: A total of 24 NSCLC patients were included in the study, 22 progressing to tyrosine kinase inhibitors and two to other treatments.

Response to crizotinib in a non-small-cell lung cancer patient harboring an fusion with an atypical insertion.

Fusion of the anaplastic lymphoma receptor tyrosine kinase gene () with the echinoderm microtubule-associated protein 4 gene () is the second most common actionable alteration in non-small-cell lung cancer, with a frequency of 5%. Here, we present a case of an EML4-ALK-positive patient with an atypical in-frame insertion from the gene in the canonical junction of . The patient was a 39-year-old never-smoker female diagnosed with Stage IV lung adenocarcinoma.